Melanie Brennan, APRN
Family · Wesley Chapel, FLNPI 1356914782
Payments from drug & device makers
Across 200 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$917
- AbbVie$570
- Pfizer$381
- Astellas Pharma US Inc$277
- GSK$235
- Lilly USA, LLC$192
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,79498%
- Education$792%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $917 |
| AbbVie | 29 | $570 |
| Pfizer | 19 | $381 |
| Astellas Pharma US Inc | 9 | $277 |
| GSK | 13 | $235 |
| Lilly USA, LLC | 11 | $192 |
| Sumitomo Pharma America, Inc. | 8 | $142 |
| Exact Sciences | 7 | $120 |
| Esperion Therapeutics, Inc. | 6 | $118 |
| AstraZeneca | 6 | $106 |
| Hologic Sales And Service, LLC | 4 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $98 |
| Sanofi-aventis U.S. LLC | 3 | $85 |
| Bayer | 3 | $81 |
| Boehringer Ingelheim | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Amgen | 2 | $38 |
| Dynavax Technologies Corporation | 1 | $32 |
| Lundbeck LLC | 1 | $28 |
| Medtronic | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Lucid Diagnostics Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Novartis | 1 | $15 |
| Merck | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
How this compares
$3,873 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $207,693 |
| EliquisApixaban | 36 | $37,900 |
| JardianceEmpagliflozin | 25 | $29,820 |
| RybelsusSemaglutide | 16 | $26,219 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $20,031 |
| LinzessLinaclotide | 15 | $18,001 |
| MyrbetriqMirabegron | 23 | $17,362 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $14,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,756 |
| MounjaroTirzepatide | 11 | $13,099 |
| FarxigaDapagliflozin Propanediol | 15 | $12,748 |
| LyricaPregabalin | 11 | $9,523 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,454 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $5,302 |
| SynthroidLevothyroxine Sodium | 69 | $4,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $917 | $233,912186 claims |
| PfizerEliquis, Lyrica | $381 | $47,42347 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $106 | $32,77940 claims |
| Boehringer IngelheimJardiance | $47 | $29,82025 claims |
| AbbVieLinzess, Synthroid | $570 | $22,74684 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $235 | $22,21032 claims |
| Astellas Pharma US IncMyrbetriq | $277 | $17,36223 claims |
| MerckJanumet | $14 | $14,85912 claims |
| Lilly USA, LLCMounjaro | $192 | $13,09911 claims |
| Sanofi-aventis U.S. LLCLantus | $85 | $4,51617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Wesley Chapel
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.